Home » Stocks » ABBV » Company

AbbVie Inc. (ABBV)

Stock Price: $118.19 USD 0.65 (0.55%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $118.15 -0.04 (-0.03%) Jul 23, 7:59 PM
AbbVie Inc.
Country United States
Industry Drug Manufacturers-General
Sector Healthcare
Employees 48,000
CEO Richard Gonzalez

Contact Details

Address:1 N Waukegan Rd
North Chicago, Illinois 60064-1802
United States
Phone 847 932 7900

Stock Information

Ticker Symbol ABBV
Exchange NYSE
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001551152
CUSIP Number 00287T100
ISIN Number US00287Y1091
Employer ID 32-0375147

Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.

In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production.

The company was incorporated in 2012 and is based in North Chicago, Illinois.

Key Executives

Richard A. GonzalezChairman and Chief Executive Officer
Dr. Michael E. SeverinoVice Chairman and Pres
Robert A. MichaelExecutive Vice President and Chief Financial Officer
Laura J. SchumacherVice Chairman of External Affairs, Chief Legal Officer and Corporate Secretary
Dr. Azita Saleki-GerhardtExecutive Vice President of Operations
Dr. Thomas J. HudsonSenior Vice President of Research & Development and Chief Scientific Officer
Elizabeth SheaVice President of Investor Relations
Timothy J. RichmondExecutive Vice President and Chief Human Resources Officer
Dr. Scott C. Brun M.D.Vice President of Scientific Affairs and Head of AbbVie Ventures
Henry O. GosebruchExecutive Vice President and Chief Strategy Officer